Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study.

被引：0
|
作者：
Sunkureddi, P. [1 ]
Toth, E. [2 ]
Brown, J. P. [3 ,4 ]
Moericke, R. [5 ]
Richard, D. [6 ]
Lheritier, K. [6 ]
Stancati, A. [6 ]
Kivitz, A. [7 ]
机构：
[1] Clear Lake Rheumatol, Nassau Bay, TX USA
[2] Flor Francis Hosp, Dept Rheumatol, Kistarcsa, Hungary
[3] CHU Quebec, Res Ctr, Quebec City, PQ, Canada
[4] Univ Laval, Quebec City, PQ, Canada
[5] Inst Pravent Med & Klin Forsch GbR, Magdeburg, Germany
[6] Novartis Pharma AG, Basel, Switzerland
[7] Altoona Ctr Clin Res, Duncansville, PA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
174
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
    Brunner, Hermine I.
    Akikusa, Jonathan D.
    Al-Abadi, Eslam
    Bohnsack, John F.
    Boteanu, Alina Lucica
    Chedeville, Gaelle
    Cuttica, Ruben
    De La Pena, Wendy
    Jung, Lawrence
    Kasapcopur, Ozgur
    Kobusinska, Katarzyna
    Schulert, Grant S.
    Neiva, Claudia
    Rivas-Chacon, Rafael
    Rizo Rodriguez, Juan Cruz
    Vazquez-Del Mercado, Monica
    Wagner-Weiner, Linda
    Weiss, Jennifer E.
    Wouters, Carine
    Posner, Holly
    Wouters, Ann
    Chang, Cheng
    White, Claire
    Kanik, Keith
    Liu, Shixue
    Martini, Alberto
    Lovell, Daniel J.
    Ruperto, Nicolino
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (11) : 1561 - 1571
  • [42] Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
    Brunner, Hermine I.
    Akikusa, Jonathan D.
    Al-Abadi, Eslam
    Bohnsack, John F.
    Boteanu, Alina Lucica
    Chedeville, Gaelle
    Cuttica, Ruben
    De La Pena, Wendy
    Jung, Lawrence
    Kasapcopur, Ozgur
    Kobusinska, Katarzyna
    Schulert, Grant S.
    Neiva, Claudia
    Rivas-Chacon, Rafael
    Rizo Rodriguez, Juan Cruz
    Vazquez-Del Mercado, Monica
    Wagner-Weiner, Linda
    Weiss, Jennifer E.
    Wouters, Carine
    Posner, Holly
    Wouters, Ann
    Chang, Cheng
    White, Claire
    Kanik, Keith
    Liu, Shixue
    Martini, Alberto
    Lovell, Daniel J.
    Ruperto, Nicolino
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (11) : 1561 - 1571
  • [43] Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study
    Tanaka, Yoshiya
    Yamamoto, Kazuhiko
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Ishiguro, Naoki
    Eguchi, Katsumi
    Watanabe, Akira
    Origasa, Hideki
    Shoji, Toshiharu
    Miyasaka, Nobuyuki
    Koike, Takao
    MODERN RHEUMATOLOGY, 2014, 24 (05) : 725 - 733
  • [44] Long-Term Safety and Efficacy of Tabalumab, an Anti-B-Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis: A 52-Week, Open-Label Extension Study.
    Greenwald, Maria W.
    Szczepanski, Leszek
    Kennedy, Alastair C.
    Lee, Chin H.
    Polasek, Emery
    Veenhuizen, Melissa
    Jones-Taha, Rebecca
    Berclaz, Pierre-Yves
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S193 - S194
  • [45] Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension
    Gadelha, Monica
    Snyder, Peter J.
    Witek, Przemyslaw
    Bex, Marie
    Belaya, Zhanna
    Turcu, Adina F.
    Feelders, Richard A.
    Heaney, Anthony P.
    Paul, Michaela
    Pedroncelli, Alberto M.
    Auchus, Richard J.
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [46] Safety and efficacy outcomes from the long-term extension study of tolebrutinib in patients with relapsing MS: Year 1 results
    Oh, J.
    Syed, S.
    Orogun, L.
    Matta, A.
    Dukovic, D.
    Fox, R.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 571 - 572
  • [47] Efficacy and Safety of Switching from Adalimumab to Baricitinib: Long-Term Data from Phase 3 Extension Study in Patients with Rheumatoid Arthritis
    Weinblatt, Michael E.
    Taylor, Peter C.
    Keystone, Edward C.
    Ortmann, Robert A.
    Issa, Maher
    Xie, Li
    de Bono, Stephanie
    Tanaka, Yoshiya
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [48] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from a Phase 3 Study
    Mease, Philip J.
    Okada, Masato
    Kishimoto, Mitsumasa
    Shuler, Catherine L.
    Carlier, Hilde
    Lin, Chen-Yen
    Mou, Jiani
    Moriarty, Susan R.
    Lee, Chin H.
    Gladman, Dafna D.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [49] Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial
    Jeyaratnam, Jerold
    Simon, Anna
    Calvo, Inmaculada
    Constantin, Tamas
    Shcherbina, Anna
    Hofer, Michael
    Gattorno, Marco
    Martini, Alberto
    Bader-Meunier, Brigitte
    Vastert, Bas
    Levy, Jeremy
    Dekker, Elise
    de Benedetti, Fabrizio
    Frenkel, Joost
    RHEUMATOLOGY, 2022, 61 (05) : 2088 - 2094
  • [50] Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
    Philip J. Mease
    Herbert Kellner
    Akimichi Morita
    Alan J. Kivitz
    Stella Aslanyan
    Steven J. Padula
    Andrew S. Topp
    Ann Eldred
    Frank Behrens
    Kim A. Papp
    Rheumatology and Therapy, 2022, 9 : 1361 - 1375
12345